Recursion Pharmaceuticals annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Stock-Based Compensation Growth & History (RXRX)
Recursion Pharmaceuticals's stock-based compensation was $111.2M for fiscal 2025.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $111.2M | $29.5M | +36.16% |
| 2024 | 2024-12-31 | $81.7M | $28.2M | +52.68% |
| 2023 | 2023-12-31 | $53.5M | $25.6M | +91.71% |
| 2022 | 2022-12-31 | $27.9M | $13.1M | +88.04% |
| 2021 | 2021-12-31 | $14.8M | $10.6M | +245.81% |
| 2020 | 2020-12-31 | $4.3M | $2.9M | +209.89% |
| 2019 | 2019-12-31 | $1.4M | — | — |
Recursion Pharmaceuticals quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.5M | −$6.7M | −25.46% |
| Q1 2026 | 2026-03-31 | $22.2M | −$13.8M | −38.39% |
| Q4 2025 | 2025-12-31 | $23.8M | −$7.0M | −22.81% |
| Q3 2025 | 2025-09-30 | $25.2M | $7.0M | +38.30% |
| Q2 2025 | 2025-06-30 | $26.2M | $9.6M | +58.31% |
| Q1 2025 | 2025-03-31 | $36.1M | $19.9M | +123.59% |
| Q4 2024 | 2024-12-31 | $30.8M | $14.7M | +91.37% |
| Q3 2024 | 2024-09-30 | $18.3M | $1.5M | +8.70% |
| Q2 2024 | 2024-06-30 | $16.5M | $4.7M | +39.90% |
| Q1 2024 | 2024-03-31 | $16.1M | $7.3M | +82.97% |
| Q4 2023 | 2023-12-31 | $16.1M | $8.4M | +109.04% |
| Q3 2023 | 2023-09-30 | $16.8M | $7.9M | +88.53% |
| Q2 2023 | 2023-06-30 | $11.8M | $6.1M | +108.12% |
| Q1 2023 | 2023-03-31 | $8.8M | $3.2M | +56.50% |
| Q4 2022 | 2022-12-31 | $7.7M | $3.4M | +77.26% |
| Q3 2022 | 2022-09-30 | $8.9M | $5.5M | +164.85% |
| Q2 2022 | 2022-06-30 | $5.7M | $358,000 | +6.73% |
| Q1 2022 | 2022-03-31 | $5.6M | $3.8M | +209.28% |
| Q4 2021 | 2021-12-31 | $4.3M | $3.2M | +265.40% |
| Q3 2021 | 2021-09-30 | $3.4M | $2.3M | +214.30% |
| Q2 2021 | 2021-06-30 | $5.3M | $4.5M | +591.42% |
| Q1 2021 | 2021-03-31 | $1.8M | $556,000 | +43.95% |
| Q4 2020 | 2020-12-31 | $1.2M | — | — |
| Q3 2020 | 2020-09-30 | $1.1M | — | — |
| Q2 2020 | 2020-06-30 | $769,000 | — | — |
| Q1 2020 | 2020-03-31 | $1.3M | — | — |
Recursion Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Recursion Pharmaceuticals's stock-based compensation increased from $4.3M to $111.2M, a change of $106.9M. The latest reported quarter, Q2 2026, shows $19.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals source filings ↗